Davenport & CO LLC Gilead Sciences, Inc. Transaction History

Davenport & CO LLC

$16.8 Billion
Q3 2024

A detailed history of Davenport & CO LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Davenport & CO LLC holds 73,579 shares of GILD stock, worth $6.64 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

73,579

Previous 69,201 6.33%

Holding current value

$6.64 Million

Previous $4.75 Million 29.91%

% of portfolio

0.04%

Previous 0.03%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	BUY	$66.59 - $83.99 $291,531 - $367,708	4,378 Added 6.33%	73,579 $6.17 Million
Q2 2024 Aug 06, 2024	BUY	$63.15 - $72.88 $430,683 - $497,041	6,820 Added 10.93%	69,201 $4.75 Million
Q1 2024 May 03, 2024	BUY	$71.58 - $87.29 $1.04 Million - $1.26 Million	14,475 Added 30.22%	62,381 $4.57 Million
Q4 2023 Jan 23, 2024	SELL	$73.27 - $83.09 $152,987 - $173,491	-2,088 Reduced 4.18%	47,906 $3.88 Million
Q3 2023 Oct 17, 2023	SELL	$73.94 - $80.67 $109,726 - $119,714	-1,484 Reduced 2.88%	49,994 $3.75 Million
Q2 2023 Jul 20, 2023	SELL	$76.01 - $86.7 $666,075 - $759,752	-8,763 Reduced 14.55%	51,478 $3.97 Million
Q1 2023 Apr 27, 2023	SELL	$77.31 - $88.08 $2.15 Million - $2.44 Million	-27,747 Reduced 31.53%	60,241 $5 Million
Q4 2022 Jan 20, 2023	SELL	$62.32 - $89.47 $754,383 - $1.08 Million	-12,105 Reduced 12.09%	87,988 $0
Q3 2022 Oct 11, 2022	BUY	$59.54 - $68.01 $362,598 - $414,180	6,090 Added 6.48%	100,093 $6.18 Million
Q2 2022 Jul 18, 2022	BUY	$57.72 - $65.01 $683,693 - $770,043	11,845 Added 14.42%	94,003 $5.81 Million
Q1 2022 May 02, 2022	BUY	$57.92 - $72.58 $817,482 - $1.02 Million	14,114 Added 20.74%	82,158 $4.88 Million
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $238,433 - $270,627	-3,675 Reduced 5.12%	68,044 $4.94 Million
Q3 2021 Oct 14, 2021	BUY	$67.69 - $73.03 $1.03 Million - $1.11 Million	15,234 Added 26.97%	71,719 $5.01 Million
Q2 2021 Jul 28, 2021	BUY	$63.47 - $69.35 $2.35 Million - $2.57 Million	37,002 Added 189.92%	56,485 $3.89 Million
Q1 2021 Apr 28, 2021	BUY	$60.0 - $68.46 $53,100 - $60,587	885 Added 4.76%	19,483 $1.26 Million
Q4 2020 Jan 13, 2021	BUY	$56.65 - $64.55 $149,102 - $169,895	2,632 Added 16.49%	18,598 $1.08 Million
Q3 2020 Oct 15, 2020	BUY	$62.1 - $78.08 $33,782 - $42,475	544 Added 3.53%	15,966 $1.01 Million
Q2 2020 Jul 28, 2020	BUY	$72.34 - $84.0 $375,299 - $435,792	5,188 Added 50.69%	15,422 $1.19 Million
Q1 2020 May 05, 2020	SELL	$62.63 - $80.22 $36,074 - $46,206	-576 Reduced 5.33%	10,234 $765,000
Q4 2019 Jan 22, 2020	BUY	$61.62 - $67.78 $293,311 - $322,632	4,760 Added 78.68%	10,810 $702,000
Q3 2019 Oct 16, 2019	SELL	$62.51 - $69.0 $32,192 - $35,535	-515 Reduced 7.84%	6,050 $409,000
Q2 2019 Jul 10, 2019	BUY	$61.87 - $69.38 $18,499 - $20,744	299 Added 4.77%	6,565 $444,000
Q1 2019 Apr 17, 2019	BUY	$62.53 - $70.05 $12,631 - $14,150	202 Added 3.33%	6,266 $407,000
Q4 2018 Jan 28, 2019	SELL	$60.54 - $79.0 $3,874 - $5,056	-64 Reduced 1.04%	6,064 $379,000
Q3 2018 Oct 11, 2018	SELL	$71.28 - $78.92 $51,250 - $56,743	-719 Reduced 10.5%	6,128 $473,000
Q2 2018 Jul 09, 2018	SELL	$64.88 - $75.68 $221,889 - $258,825	-3,420 Reduced 33.31%	6,847 $485,000
Q1 2018 Apr 04, 2018	SELL	$72.84 - $88.8 $243,795 - $297,213	-3,347 Reduced 24.58%	10,267 $774 Million
Q4 2017 Jan 17, 2018	SELL	$71.15 - $83.52 $33.5 Million - $39.3 Million	-470,454 Reduced 97.19%	13,614 $975 Million
Q3 2017 Oct 12, 2017	BUY	$72.11 - $85.47 $34.9 Million - $41.4 Million	484,068	484,068 $39.2 Billion

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Davenport & CO LLC with notifications on news.

Account